RU2021126744A - A kit and a single dosage form for the prevention of type 1 diabetes, their use for the prevention of type 1 diabetes, a method for the prevention of type 1 diabetes in healthy people from a high-risk group - Google Patents

A kit and a single dosage form for the prevention of type 1 diabetes, their use for the prevention of type 1 diabetes, a method for the prevention of type 1 diabetes in healthy people from a high-risk group Download PDF

Info

Publication number
RU2021126744A
RU2021126744A RU2021126744A RU2021126744A RU2021126744A RU 2021126744 A RU2021126744 A RU 2021126744A RU 2021126744 A RU2021126744 A RU 2021126744A RU 2021126744 A RU2021126744 A RU 2021126744A RU 2021126744 A RU2021126744 A RU 2021126744A
Authority
RU
Russia
Prior art keywords
type
gaba
diabetes
prevention
dpp
Prior art date
Application number
RU2021126744A
Other languages
Russian (ru)
Inventor
Шмуэль Борис Левит
Original Assignee
Левикуре Лтд.
Filing date
Publication date
Application filed by Левикуре Лтд. filed Critical Левикуре Лтд.
Priority to PCT/IB2022/000446 priority Critical patent/WO2023037160A2/en
Publication of RU2021126744A publication Critical patent/RU2021126744A/en

Links

Claims (10)

1. Набор для ежедневного перорального приёма для профилактики сахарного диабета 1 типа, включающий эффективные количества веществ из 1) группы ингибиторов дипептидилпептидазы (ДПП-4), 2) группы ингибиторов протонного насоса (ИПП), 3) гамма аминомасляной кислоты (ГАМК) или агониста рецепторов ГАМК.1. A daily oral kit for the prevention of type 1 diabetes mellitus, comprising effective amounts of substances from 1) the dipeptidyl peptidase (DPP-4) inhibitor group, 2) the proton pump inhibitor (PPI) group, 3) gamma-aminobutyric acid (GABA) or an agonist GABA receptors. 2. Набор по п.1, отличающийся тем, что включает количество ингибитора ДПП-4 от 25 до 100 мг, количество ИПП от 10 до 40 мг, количество препарата ГАМК или агониста рецепторов ГАМК от 125 до 1500 мг.2. The kit according to claim 1, characterized in that it includes an amount of a DPP-4 inhibitor from 25 to 100 mg, an amount of PPI from 10 to 40 mg, an amount of a GABA drug or a GABA receptor agonist from 125 to 1500 mg. 3. Набор по п.1, характеризующийся тем, что препарат группы ингибиторов ДПП-4 представляет собой ситаглиптин, препарат группы ИПП представляет собой омепразол.3. The kit according to claim 1, characterized in that the drug of the DPP-4 inhibitor group is sitagliptin, the drug of the PPI group is omeprazole. 4. Разовая дозированная форма, вводимая перорально, для профилактики сахарного диабета 1 типа, содержащая эффективные количества 1) ДПП-4, 2) ИПП и 3) препарата ГАМК или агониста рецептора ГАМК.4. A single oral dosage form for the prevention of type 1 diabetes mellitus containing effective amounts of 1) DPP-4, 2) PPI, and 3) a GABA drug or GABA receptor agonist. 5. Разовая дозированная форма по п.4, в которой количество ингибитора ДПП-4 составляет от 25 до 100 мг, количество ИПП составляет от 10 до 40 мг, а количество ГАМК или агониста ГАМК составляет от 125 до 1500 мг.5. The unit dosage form of claim 4, wherein the amount of DPP-4 inhibitor is 25 to 100 mg, the amount of PPI is 10 to 40 mg, and the amount of GABA or GABA agonist is 125 to 1500 mg. 6. Разовая дозированная форма по п.4, отличающаяся тем, что ингибитор ДПП-4 представляет собой ситаглиптин, а ИПП представляет собой омепразол.6. A single dosage form according to claim 4, characterized in that the DPP-4 inhibitor is sitagliptin and the PPI is omeprazole. 7. Применение пероральной комбинации, включающей действующие вещества из 1) группы ингибиторов ДПП-4, 2) группы ИПП, 3) ГАМК или агониста рецепторов ГАМК, для профилактики сахарного диабета 1 типа.7. The use of an oral combination, including active substances from 1) the group of DPP-4 inhibitors, 2) the group of PPIs, 3) GABA or GABA receptor agonist, for the prevention of type 1 diabetes mellitus. 8. Способ профилактики сахарного диабета 1 типа, включающий введение лицам из группы высокого риска развития сахарного диабета 1 типа комбинации, представляющей собой набор по п.1, или дозированных форм по п.7.8. A method for the prevention of type 1 diabetes mellitus, comprising administering to persons at high risk of developing type 1 diabetes a combination, which is a set according to claim 1, or dosage forms according to claim 7. 9. Способ по п.8, отличающийся тем, что к группе высокого риска развития сахарного диабета 1 типа относят имеющих по меньшей мере одного родителя, и/или сибса, и/или ребёнка с установленным диагнозом «сахарный диабет 1 типа». 9. The method according to claim 8, characterized in that the high risk group for developing type 1 diabetes includes having at least one parent and/or sibling and/or a child diagnosed with type 1 diabetes. 10. Способ по п.8, отличающийся тем, что вводят в сутки от 25 до 100 мг ингибитора ДПП-4, от 10 до 40 мг ИПП, от 125 до 1500 мг ГАМК или агониста рецепторов ГАМК. 10. The method according to claim 8, characterized in that 25 to 100 mg of a DPP-4 inhibitor, 10 to 40 mg of PPI, 125 to 1500 mg of GABA or a GABA receptor agonist are administered per day.
RU2021126744A 2021-09-10 2021-09-10 A kit and a single dosage form for the prevention of type 1 diabetes, their use for the prevention of type 1 diabetes, a method for the prevention of type 1 diabetes in healthy people from a high-risk group RU2021126744A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2022/000446 WO2023037160A2 (en) 2021-09-10 2022-08-16 Kit and single-use dosage form for the prophylaxis of type 1 diabetes mellitus, use of same for the prophylaxis of type 1 diabetes mellitus, method for the prophylaxis of type 1 diabetes mellitus in healthy individuals in a high-risk group

Publications (1)

Publication Number Publication Date
RU2021126744A true RU2021126744A (en) 2023-03-10

Family

ID=

Similar Documents

Publication Publication Date Title
Scheen Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
Eschlböck et al. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
Alagiakrishnan et al. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer’s disease
Watson et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study
US11963961B2 (en) Combination therapy comprising an ACC inhibitor
Kim et al. Management of type 2 diabetes mellitus in older adults
Del Prato et al. Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
Kamen et al. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury
JP2017145251A (en) Therapy for complications of diabetes
Sinclair et al. Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotype
US8865747B2 (en) Pioglitazone for use in the treatment of adrenoleukodystrophy
Arbo et al. Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
Mami et al. Effect of opium addiction on some serum parameters in rabbit
HRP20231177T1 (en) A combination of substances for use in regenerative therapy in patients with type 1 diabetes mellitus
RU2021126744A (en) A kit and a single dosage form for the prevention of type 1 diabetes, their use for the prevention of type 1 diabetes, a method for the prevention of type 1 diabetes in healthy people from a high-risk group
US20170273957A1 (en) Antitussive compositions and methods
Tago et al. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus
Barzilay et al. Consensus statement by the American Association of Clinical endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary
JP2019519480A (en) Use of Acetylcholinesterase Inhibitor and Idaropirdin to Reduce Fall in Parkinson's Disease Patients
Choi et al. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers
Clive et al. Nonsteroidal antiinflammatory drugs and opioids in chronic kidney disease
US20060089412A1 (en) Pharmaceutical composition for the treatment of non-alcoholic fatty liver disease
JP6416213B2 (en) Nalmefene for the treatment of patients with mood disorders
WO2023037160A3 (en) Kit and single dosage form for the prevention of type 1 diabetes mellitus in healthy people from high-risk group
JP2019514978A (en) Treatment of alcoholism and depression and / or unpleasant mood using ibudilast